Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2003

01-06-2003 | Originales

Determination of c-erbB-2/Her-2/Neu status in breast cancer: comparative analysis between immunoenzymatic assay (ELISA) and immunohistochemistry

Authors: María L. Lamelas Suárez-Pola, Luis O. González Vázquez, Antonio Rodil Díaz, Miguel Bongera García, Julio Vázquez Rojo, María T. Allende, Francisco Vizoso Piñeiro

Published in: Clinical and Translational Oncology | Issue 5/2003

Login to get access
Metadata
Title
Determination of c-erbB-2/Her-2/Neu status in breast cancer: comparative analysis between immunoenzymatic assay (ELISA) and immunohistochemistry
Authors
María L. Lamelas Suárez-Pola
Luis O. González Vázquez
Antonio Rodil Díaz
Miguel Bongera García
Julio Vázquez Rojo
María T. Allende
Francisco Vizoso Piñeiro
Publication date
01-06-2003
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2003
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02711483

Other articles of this Issue 5/2003

Clinical and Translational Oncology 5/2003 Go to the issue

Revisiones

Tratamiento del cáncer de esófago localizado y localmente avanzado: ¿algo ha cambiado?

Notas Clínicas

Stereotactic extracraneal radiosurgery: single liver metastasis treated with stereotactic body frame

Originales Breves

Obtaining new formulations of inclusion resin for optical microscopy. Introduction of its use in animal tissue

Notas Clínicas

Infiltrative squamous-cell carcinoma arising in perianal buschke-lowenstein tumour: Successful treatment with surgical excision

Editorial

Science Foundations in cancer research: scope and perspectives

Correspondencia

ιHace falta una nueva concepción de los cuidados paliativos en oncología?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits